A randomized trial (MA.17R) of extending adjuvant letrozole for 5
years after completing an initial 5 years of aromatase inhibitor
therapy alone or preceded by tamoxifen in postmenopausal women
with early-stage breast cancer.
Dr. Roberto Torres
Pathologic complete response rates after neoadjuvant trastuzumab
emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin +
trastuzumab + pertuzumab treatment in patients with HER2-positive
early breast cancer.
Dra. Christina Adaniel
Abstract 507: PALOMA-2
Primary results from a phase 3 trial of palbociclib (P) with letrozole (L)
compared with letrozole alone in postmenopausal women with
ER+/HER2– advanced breast cancer (ABC).
Dr. Francisco Acevedo
A randomized controlled trial evaluating resection of the primary
breast tumor in women presenting with de novo stage IV breast
cancer: Turkish Study (Protocol MF07-01)
Dra. Alejandra Quintas
Abstract 1007: Ten-year survival
Results of ACOSOG Z0011: A randomized trial of axillary node
dissection in women with clinical T1-2 N0 M0 breast cancer who have
a positive sentinel node (Alliance).
Dr. Moisés Russo